CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...